Novel dry particle coating technology for the development of dry powder inhalation formulations

点击翻译按钮获取中文摘要

The global market for treatment of asthma and COPD is estimated to be $41.7B in 2017. Dry powder inhalers (DPI) make up nearly 50% of the market by sales value (FDA, 2015). The formulation and performance of a DPI is affected by complex interactions between drug substance, excipients and inhalation device. Current technologies for developing DPIs, such as high shear blending or turbula mixing remain a black art based on trial and error, with highly variable inputs to the subsequent DPI formulation. APT offers a world’s first IP protected (WO 2016/066462A) aerosolised particle engineering technology as a one step, relatively isothermal process with controlled process parameters that produces repeatable product performance with readily available commercial excipients. APT can offer a means of streamlining preclinical formulation development, whilst simultaneously providing robust clinical test article. APT will target the market through product development fees and licensing for royalty payment. The team brings over 75 years of pharma experience and comprises of Dr Ian Smith (CEO), Dr David Wyatt (COO), Prof Afzal Mohammed (CTO), 2FTE scientists and project manager. The CEO and COO have many contacts in DPI sector including GSK, Vectura, Novartis and Mylan.